Navigation Links
Pharmatech Oncology to Present at 46th Annual DIA Meeting
Date:6/13/2010

DENVER, June 11 /PRNewswire/ -- On Wednesday June 16, Pharmatech Oncology will chair a session at the 46th Annual DIA Meeting to discuss patient-focused clinical research systems in the age of personalized cancer medicine. Speakers will include Jeffrey Vacirca MD, Director of Clinical Research at North Shore Hematology/Oncology Associates in East Setauket, NY and Matt Baker, President and CEO of Compass IRB in Mesa, AZ.

Dr. Vacirca will discuss the concept of personalized cancer research by reevaluating the site-based research paradigm and the development of a patient focused solution known as Just-In-Time.  Matt Baker will present the development of IRB systems in alignment with the requirements of patient-first research. Furthermore, he will discuss protection of patient rights and regulatory compliance in the modern research setting.  Session chair, Eric Lynam, VP of Business Development at Pharmatech Oncology, comments, "This is a very exciting period in cancer therapeutic research, and the time is at hand to personalize the clinical research process as we focus increasingly on precision cancer medicine.  This session is intended to stimulate discussion and new ideas among pharmaceutical companies, research organizations, physicians, patients, and patient advocates, with a goal toward putting patients first in clinical trials and developing solutions to bring better cancer medicines into the clinic faster."

The Just-In-Time solution is a patient-focused approach that enables research centers to proactively look for clinical trial candidate patients prior to study initiation. Once a potential study patient is identified (using standard-of-care procedures), the site is initiated in an expedited manner. In spite of the challenges involved in clinical trials for patients with rare cancers, Just-In-Time continues to demonstrate that US-based studies can accrue efficiently, while significantly mitigating cost and time related risks. This methodology represents an important step toward a more effective clinical trial system, aligned with the needs of precision cancer treatment. Just-In-Time continues to evolve, setting a new standard for time to first patient enrolled, enrollment rate, and overall patient accrual.

Pharmatech Oncology, headquartered in Denver, Colorado, is a Research Management Organization (RMO) dedicated to the highest quality of clinical research. Pharmatech Oncology provides oncology-specific Site Management Organization (SMO) and Contract Research Organization (CRO) services to its network of primarily community-based clinics. While experienced in oncology studies, the company's separate Data Management business entity is also capable of providing services for research projects in other disease indications. Pharmatech Oncology's dedication to rapid enrollment and quality data ensures successful development and utilization of therapeutic products among sponsors, investigators, and patients.

About Pharmatech Oncology, Inc.:

Pharmatech Oncology, headquartered in Denver, Colorado, is a Research Management Organization (RMO) dedicated to the highest quality of clinical research. Pharmatech Oncology provides oncology-specific Site Management Organization (SMO) and Contract Research Organization (CRO) services to its network of primarily community-based clinics. While experienced in oncology studies, the company's separate Data Management business entity is also capable of providing services for research projects in other disease indications . Pharmatech Oncology's dedication to rapid enrollment and quality data ensures successful development and utilization of therapeutic products among sponsors, investigators, and patients.

For more information about Pharmatech, please visit www.pharmatechoncology.com.

For more information about Compass IRB, please visit www.compassirb.com

Key words: Cancer, clinical trials, contract research, oncology, patients, research, site management


'/>"/>
SOURCE Pharmatech Oncology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 2007
2. WuXi PharmaTech Announces Second Quarter 2007 Results
3. WuXi PharmaTech (NYSE: WX) Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia
4. WuXi PharmaTech (NYSE: WX) Ranked the 28th of Deloitte Technology Fast 50 China
5. Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech
6. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
7. WuXi PharmaTech (NYSE: WX) Promotes Edward Hu to COO
8. WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc.
9. WuXi PharmaTech (NYSE: WX) CEO Honored among the 2007 China Top 10 Influential Entrepreneurs
10. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
11. WuXi PharmaTech Completes Acquisition of AppTec
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... , ... STACS DNA Inc., the sample tracking software company, today announced that ... joined STACS DNA as a Field Application Specialist. , “I am thrilled that ... of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... , June 23, 2016 ... Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 Published ... the peer-reviewed journal from touchONCOLOGY, Andrew D ... cost of cancer care is placing an increasing ... of expensive biologic therapies. With the patents on ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
Breaking Biology Technology:
(Date:6/9/2016)... June 9, 2016 Paris ... Teleste,s video security solution to ensure the safety of people ... during the major tournament Teleste, an international ... and services, announced today that its video security solution will ... to back up public safety across the country. The system ...
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
(Date:5/20/2016)... May 20, 2016  VoiceIt is excited to ... VoicePass. By working together, VoiceIt and ... VoiceIt and VoicePass take slightly different approaches to ... both security and usability. ... this new partnership. "This marketing and ...
Breaking Biology News(10 mins):